PAUL STEVEN M 4
4 · Rapport Therapeutics, Inc. · Filed Sep 15, 2025
Insider Transaction Report
Form 4
PAUL STEVEN M
Director
Transactions
- Purchase
Common Stock
2025-09-12$24.50/sh+28,284$692,947→ 28,284 total(indirect: By LLC) - Purchase
Common Stock
2025-09-12$24.97/sh+13,382$334,165→ 41,666 total(indirect: By LLC)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $23.90 to $24.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.
- [F2]Shares held by Paul Capital Strategy III Fund LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
- [F3]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $24.90 to $25.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.